We use cookies for certain features and to improve your experience. See our Cookie Policy and Privacy Policy to learn more

Leafly

Shop legal, local weed.

Open
advertise on Leafly
ShopDeliveryDispensariesDealsStrainsBrandsProductsCBDDoctorsCannabis 101Social impact
  • Sign in
  • Create account
  • Strains
  • Shop
  • Shop
  • Delivery
  • Deals
  • Dispensaries
  • CBD Stores
  • Brands
  • Products
  • Learn
  • Cannabis 101
  • News
  • Leafly Learn
  • Science of cannabis
  • Doctors
  • Social impact
  • Lab partners
  • Download the Leafly App
  • Advertise on Leafly
    • Leafly.comUSA flag
    • Leafly.caCanadian flag
    • Leafly.deGerman flag
  • Help
  • News
  • Lifestyle
  • Strains & products
  • Industry
  • Growing
  • Health
  • Science & tech
  • Leafly USA
  • Podcasts
  • Learn
Politics

National cannabis advocates demand end to blockade of Washington DC’s adult-use market

Calvin StovallPublished on November 14, 2022
(AdobeStock)

The ACLU, DPA, and Dr. Bronner’s are using election momentum to push for a legal adult-use market in Washington DC, which was approved by voters back in 2014.


In 2014, voters in Washington DC overwhelmingly voted to legalize possession of up to two ounces of cannabis, as well as home-grow of up to six plants, and gifting of up to an ounce. Nearly a decade later, the commercial market is still on hold. And while medical and gray markets have helped fill the gap, some major local, state, and national organizations have had enough. So they wrote a letter to the Biden Administration demanding action.

Advocates led by the Drug Policy Alliance signed a letter to Attorney General Merrick Garland pushing for a non-enforcement approach that would end the current legislation blocking the District from launching a legal and regulated adult-use market.

The coalition also includes the ACLU, NORML, and the soap aficionados at Dr. Bronner’s. The advocates are backed by the wind of pro-420 advances in last week’s election, and progress last month from President Biden, who directed all state governments to release non-violent cannabis prisoners.

merrick-garland
Merrick Garland, once blocked as an Obama Supreme Court nominee, became Joe Biden’s nominee for attorney general. (AP Photo/Andrew Harnik)

The letter calls for an end to the Harris rider, which was signed about a month after DC voters approved legalization through ballot measure Initiative 71 (I-71). Months after the 2014 vote, Maryland Rep. Andy Harris effectively blocked commercial sales in the District with a rider that prevents the DC Council from adopting comprehensive regulations for a legal cannabis industry.

The same Andy Harris made up racist facts to justify his active blockade of DC legalization in 2016. His stance is clear.

Back in the early days of the Trump Administration, then-Attorney General Jeff Sessions further complicated things in 2018 by rescinding the Cole Memo, which protected state-licensed businesses from federal cannabis laws. Without the Cole Memo’s protections, and with the Harris rider’s restrictions in place, DC regulators have their hands tied in regards to rolling out the regulations that would allow a licensed market to move forward.

The newest workaround is a medical marijuana self-certification program that was launched in June, which allows virtually any adult to prescribe themselves access to DC’s licensed and regulated medical market. The District’’s patient count has grown by 55% since self-certification was signed into law by Mayor Muriel Bowser. But it’s still a workaround. The Harris rider could be permanently removed from the 2023 Fiscal Year budget through Congressional legislation—which is less likely if Republicans take control of the House—or action from Merrick Garland if the coalition gets what the letter asks for.

In total, 75 organizations signed the request for a non-enforcement approach, calling for an end to the Harris rider and the related Anti-Deficiency Act, which keeps DC as the “only jurisdiction in the country that cannot regulate marijuana sales or fruitfully tap into the public health and safety benefits of proper regulation,” according to the letter.

“We recognize that not everyone in Congress supports DC’s right to become a State, which would ensure the rights and liberties of its diverse, voting, tax paying, military serving residents. Nevertheless, we collectively call on the Department of Justice to at least commit to a non-enforcement approach for DC that includes the non-enforcement of the ‘Harris’ rider and the Anti-Deficiency Act with respect to the rider, and permit DC to spend its local dollars on priorities such as regulating marijuana in the same way that 19 other States have already done… Allowing DC to regulate cannabis would alleviate public health and safety concerns due to the unregulated marijuana market in DC, promote economic development in DC, as well as demonstrate this administration’s support for DC’s right to home rule.”

Letter signed by DPA and 74 other cannabis advocates

In 2020, House Democrats tried to get DC’s market going with a funding bill that never made it to full approval. At the time, Rep. Mike Quigley (D-IL), committee chairman, said, “Americans deserve a government that will invest in the long-term protection of consumers and investors, strengthen our national security, and promote entrepreneurship here at home.. This year’s [Financial Services and General Government] funding bill takes significant steps to accomplish each of those goals.”

Shop highly rated dispensaries near you

Showing you dispensaries near
See all dispensaries
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • See all dispensaries
See all dispensaries
ACLUBiden administrationcannabis newslegalizationWashington DC
Calvin Stovall
Calvin Stovall
Calvin Stovall is Leafly's East Coast Editor.
View Calvin Stovall's articles

The latest in Politics

  • How US import tariffs are impacting cannabis prices and products image
    How US import tariffs are impacting cannabis prices and products
    Leafly Staff
  • Ohioans must activate to defend cannabis freedoms from lawmakers image
    Ohioans must activate to defend cannabis freedoms from lawmakers
    David Downs
  • Montanans must activate to protect legalization in 2025 image
    Montanans must activate to protect legalization in 2025
    David Downs
  • Analysis: Don’t hold your breath for legalization under Trump 2.0 image
    Analysis: Don’t hold your breath for legalization under Trump 2.0
    David Downs
Get good reads, local deals, and strain spotlights delivered right to your inbox.

By providing us with your email address, you agree to Leafly's Terms of Service and Privacy Policy.



Stay In Touch

Receive updates on new products, special offers, and industry news.

Something went wrong, please try again.

By providing us with your email address, you agree to Leafly’s Terms of Service and Privacy Policy.

Leafly mobile app
Get high for less.
Download the Leafly app.
Download Leafly: Marijuana Reviews on the App StoreDownload Leafly Marijuana Reviews on Google Play

Business Solutions
  • List your store
  • List your CBD store
  • List your brand
  • List your practice
  • Business log in

About Leafly
  • About us
  • Careers
  • Newsroom
  • Investor relations
  • Contact us
  • FAQs
  • Accessibility

Dispensaries in
  • Los Angeles
  • Seattle
  • Portland
  • San Francisco
  • Toronto
  • Detroit

Privacy & Terms
  • Terms of use
  • Commercial terms of use
  • Privacy policy
  • Do not sell my personal information

* Statements made on this website have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Information provided by this website or this company is not a substitute for individual medical advice.


© 2025 Leafly, LLC
Leafly and the Leafly logo are registered trademarks of Leafly, LLC. All Rights Reserved.